Volociximab is a chimeric monoclonal antibody that inhibits the functional activity of a5ß1 integrin, a protein found on activated endothelial cells. Blocking the activity of a5ß1 integrin has been found to prevent angiogenesis, the formation of new blood vessels that feed tumors and allow them to grow and metastasize.

We believe that volociximab may have potential in treating a range of solid tumors and that its role in angiogenesis may also aid in the treatment of age related macular degeneration (AMD). Currently, we have a worldwide strategic development collaboration with Biogen Idec for volociximab in oncology, and, with them, we have an out-licensing agreement with Ophthotech for its development in AMD.

Prior data and associated analyses have contributed to our understanding of the mechanism and safety profile of volociximab. We will use emerging data to either advance or terminate development of volociximab in oncology based on the current ongoing trials.

With our partner, Biogen Idec, we are currently investigating volociximab in various open-label clinical trials in patients with advanced solid tumors. This includes trials in ovarian cancer and non-small cell lung cancer (NSCLC).